Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • O'Dwyer, K.; Hackel, M.; Hightower, S.; Hoban, D.; Bouchillon, S.; Qin, D.; Aubart, K.; Zalacain, M.; Butler, D.
    Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322 (2013), Antimicrob. Agents Chemother., 57, 2333-2342.
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
3.5.1.88 (2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
 Moraxella catarrhalis
3.5.1.88 actinonin
-
 Moraxella catarrhalis
3.5.1.88 GSK1322322 an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview Haemophilus influenzae
3.5.1.88 GSK1322322 an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview Staphylococcus aureus
3.5.1.88 GSK1322322 an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview Streptococcus pyogenes
3.5.1.88 GSK1322322 an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview Streptomyces pneumoniae
3.5.1.88 N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
-
 Moraxella catarrhalis
3.5.1.88 N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview Moraxella catarrhalis

Organism

EC Number Organism UniProt Comment Textmining
3.5.1.88 Haemophilus influenzae
-
-
-
3.5.1.88 Moraxella catarrhalis
-
-
-
3.5.1.88 Staphylococcus aureus
-
-
-
3.5.1.88 Streptococcus pyogenes
-
-
-
3.5.1.88 Streptomyces pneumoniae
-
-
-

Synonyms

EC Number Synonyms Comment Organism
3.5.1.88 peptide deformylase
-
 Staphylococcus aureus
3.5.1.88 peptide deformylase
-
 Haemophilus influenzae
3.5.1.88 peptide deformylase
-
 Streptococcus pyogenes
3.5.1.88 peptide deformylase
-
 Moraxella catarrhalis
3.5.1.88 peptide deformylase
-
 Streptomyces pneumoniae